Evaluation of 1,25-dihydroxyvitamin D3 Pathway in Patients with Chronic Urticaria.

Related Articles

Evaluation of 1,25-dihydroxyvitamin D3 Pathway in Patients with Chronic Urticaria.

QJM. 2017 Nov 20;:

Authors: Nasiri-Kalmarzi R, Abdi M, Hosseini J, Babaei E, Mokarizadeh A, Vahabzadeh Z

Abstract
BACKGROUND: Previous studies showed the role of vitamin D (Vit D) on the progression of chronic urticaria. To the best of our knowledge, there are no other results regarding the contribution of single nucleotide polymorphisms (SNPs) in the vitamin D receptor (VDR) and vitamin D binding protein (VDBP) genes in Chronic Urticaria (CU).
AIM: In the present study, we investigated the Vit pathway and the association between VDR and VDBP gene polymorphisms and CU risk in Iranian population.
METHODS: All participating individuals in the present study were evaluated for serum Vit D and VDBP concentration VDR rs1544410 and rs2228570 and VDBP rs7041using a polymerase chain reaction⍰restriction fragment length polymorphism (PCR-RFLP) analysis. The associations of studied analytes and 3 SNPs with clinical and laboratory outcomes were investigated in CU patients.
RESULTS: Patients with CU showed lower Vit D compared to controls (19.26 ± 1.26 vs. 31.72 ± 7.14 ng/ml, p value=0.006). There was a significant correlation between vitamin D levels and urticaria activity score. Serum VDBP was significantly higher in CU patients than controls (1317.3 ± 183.71 vs. 395.77 ± 12.96 µg/mL, p value < 0.0001) and had a positive correlation to progression of CU. The A allele of this polymorphism might be a potential risk factor for progression of CU (OR = 4.3434, 95%CI = (1.7331 to 10.8852), Z statistic= 3.133, p value=0.0017).
CONCLUSION: In Summary, this study demonstrated that change in Vit D pathway in the level of gene or protein may be a risk factor for progression of CU.

PMID: 29165650 [PubMed - as supplied by publisher]

from #PM All via ola Kala on Inoreader http://ift.tt/2ngrRRB